Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 11,333 matching trials from the live ClinicalTrials.gov search.

Filters: Cleveland, Ohio Clear all

Conditions: Rotator Cuff Tears, Rotator Cuff Repairs
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Thrombocytopenia
Interventions: Baseline cell blood counts; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 88 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cerebrovascular Accident
Interventions: ONO-2506; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 130
States / cities: Birmingham, Alabama • Berkeley, California • La Mesa, California + 102 more

Conditions: Lipodystrophy, HIV Infections
Interventions: Tesamorelin, Placebo for Tesamorelin; Drug
Lead sponsor: Theratechnologies; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 27
States / cities: Birmingham, Alabama • Phoenix, Arizona • Indio, California + 20 more

Conditions: Prostate Cancer
Interventions: Suramin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2008
U.S. locations: 26
States / cities: Chicago, Illinois • Urbana, Illinois • Cedar Rapids, Iowa + 19 more

Conditions: Paroxysmal Atrial Fibrillation
Interventions: FlecIH-103; Drug
Lead sponsor: InCarda Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 18
States / cities: Davis, California • Long Beach, California • Bridgeport, Connecticut + 12 more

Conditions: Agglutinin Disease, Cold
Interventions: BIVV009; Drug
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 13
States / cities: Tucson, Arizona • Los Angeles, California • Whittier, California + 9 more

Conditions: Breast Cancer
Interventions: docetaxel, paclitaxel; Drug
Lead sponsor: Aventis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2004
U.S. locations: 32
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 28 more

Conditions: Brain and Central Nervous System Tumors
Interventions: hydroxychloroquine, temozolomide, pharmacological study, Radiation; Drug · Other · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 9
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Abdominal Aortic Aneurysm (AAA)
Interventions: Nellix System; Device
Lead sponsor: Endologix; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 27
States / cities: Tucson, Arizona • San Diego, California • New Haven, Connecticut + 23 more

Conditions: Coronavirus Infection, COVID-19
Interventions: Not listed
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cerebral Amyloid Angiopathy
Interventions: Placebo, ALN-APP; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 34
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 27 more

Conditions: Ulcerative Colitis
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 12
States / cities: Phoenix, Arizona • San Diego, California • San Francisco, California + 9 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Ambrisentan, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 57
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 48 more

Conditions: Lumbar Disc Disease
Interventions: BRTX-100, Saline; Biological · Drug
Lead sponsor: BioRestorative Therapies; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Santa Monica, California • Walnut Creek, California + 15 more

Conditions: Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC, Locally Advanced Metastatic NSCLC
Interventions: AMG 510; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
U.S. locations: 30
States / cities: Huntsville, Alabama • Anchorage, Alaska • Chandler, Arizona + 27 more

Conditions: Leukemia, Myeloid, Acute
Interventions: CC-486, Venetoclax; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Stanford, California • Denver, Colorado • Boston, Massachusetts + 4 more

Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: Pacritinib, Best Available Therapy; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 50
States / cities: Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Virtual Educational Program; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 16 Years to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertension, Hemorrhage
Interventions: clevidipine; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 14
States / cities: Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 11 more

Conditions: Hypertension
Interventions: ramipril; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • Augusta, Georgia + 22 more

Conditions: Cervical Cancer
Interventions: cisplatin, pemetrexed disodium; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • Jackson, Mississippi + 7 more

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: Idebenone 150 mg film-coated tablets, placebo; Drug
Lead sponsor: Santhera Pharmaceuticals; Industry
Eligibility: 10 Years and older · Male only
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 16 more

Conditions: Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Interventions: Tarlatamab, Durvalumab, Carboplatin, Etoposide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 50
States / cities: Casa Grande, Arizona • Goodyear, Arizona • Hot Springs, Arkansas + 45 more

Search by objective public record fields.

Variation in Humeral Head Bone Marrow Characteristics With Rotator Cuff Repair Healing

Collection of Peripheral Blood From Patients With Hematologic Malignancies With Thrombocytopenia

A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer

Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)

Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer

Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System

WGS Analysis of COVID-19 Positive Patients

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

Expanded Access of Sotorasib

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

Acceptability of Virtual Educational Intervention for Adolescents and Young Adults With Type 1 Diabetes Mellitus

Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)

Treatment of Pediatric Hypertension With Altace Trial

Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)